Replies to post #898 on Fate Therapeutics Inc (FATE)

[jondoeuk]

''The planned Phase 1 study will evaluate safety, tolerability, and early signs of clinical activity in patients with advanced solid cancers including lung cancer, ovarian cancer, head and neck cancer, and sarcomas. The study represents the first clinical validation of Zelluna's proprietary TCR-NK platform, and initial clinical data is expected to emerge from mid-2026.'' https://www.globenewswire.com/news-release/2026/02/11/3235940/0/en/Zelluna-selects-Medpace-as-CRO-for-ZIMA-101-first-in-human-clinical-trial.html